6 reports

Our Gastrointestinal Portfolio.

  • Gastrointestinal Drug
  • Japan
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • Ironwood Pharmaceuticals, Inc.

The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Japan
  • Product Initiative
  • RaQualia Pharma Inc.
  • YH-12852 - DRUG PROFILE

Similarly, the Universities' portfolio in Discovery stages comprises ## molecules, respectively.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Japan
  • Product Initiative
  • RaQualia Pharma Inc.

The most common adverse events occurring in Phase ## trials of SHP## were gastrointestinal in nature, predominantly diarrhea.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • Japan
  • Product Initiative
  • APR 27, 2017: ALBIREO ANNOUNCES ELOBIXIBAT DATA FROM JAPAN TO BE PRESENTED AT DDW 2017
  • ELOBIXIBAT - DRUG PROFILE

In April ##, 2016, Eisai' s gastrointestinal disease business and Ajinomoto Pharmaceuticals, with amino acids at its core, will be integrated and commence business as EA Pharma.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • Japan
  • Product Initiative

For Gastrointestinal Therapies.

  • Gastrointestinal Drug
  • Pharmaceutical
  • Japan
  • Company Operations
  • RaQualia Pharma Inc.